The prevalence of HPV16/18 in cervical cancer has been reported to decline with age in
some papers. However, whether this decline in proportion of cancers positive for HPV16/18 …

Background Assessment of the prevaccination type-specific prevalence of human
papillomavirus (HPV) in the general population is important for the prediction of the impact of …

Importance Determining vaccine dose-level protection is essential to minimize program
costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination …

Abstract Background In 2009, Norway initiated routine quadrivalent HPV (qHPV) vaccination
for girls at 12–13 years of age to protect against virus types causing cervical cancer …

Background Human papillomavirus (HPV) vaccination has shown high efficacy against anal
HPV infection and lesions in clinical trials, and the HPV prevalence and type distribution in …

Purpose Approximately 70% of cervical cancers and about 50% of high-grade cervical
precursor lesions are caused by human papillomavirus (HPV) types 16 and 18. Denmark …

An investigational monovalent human papillomavirus (HPV) 16 virus-like particle vaccine
has been shown to prevent persistent infection and cervical disease related to HPV 16 and …

Quadrivalent human papillomavirus (HPV)[types 6, 11, 16, 18] recombinant vaccine
(Gardasil®; Silgard®) is composed of virus-like particles formed by self-assembly of …

Introduction Since 2007, many countries have implemented national human papillomavirus
(HPV) vaccination programs with the quadrivalent HPV (4HPV) vaccine that has been …

Background Denmark introduced the quadrivalent human papillomavirus vaccine into the
vaccination program for 12-to 15-year-old girls in 2008 to 2009. In 2012, the program was …